Investment Bank Downgrades Invitrogen Stock, Cuts Outlook | GenomeWeb
NEW YORK (GenomeWeb News) — Investment bank Piper Jaffray cut its target price for shares in Invitrogen to $62 from $78 and downgraded its stock to “market perform” from “outperform” around two weeks after the company posted weak third-quarter financials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.